Volume 79, Issue 2 pp. 263-270
Coronary Artery Disease

Amplatzer septal occluder to treat iatrogenic cardiac perforations

Valérie Stolt MD

Valérie Stolt MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Stéphane Cook MD

Stéphane Cook MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Lorenz Räber MD

Lorenz Räber MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Sunil Wani MD

Sunil Wani MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Ali Garachamani MD

Ali Garachamani MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Rolf Vogel MD, PhD

Rolf Vogel MD, PhD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Christian Seiler MD

Christian Seiler MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Stephan Windecker MD

Stephan Windecker MD

Department of Cardiology, University Hospital, Bern, Switzerland

Search for more papers by this author
Bernhard Meier MD

Corresponding Author

Bernhard Meier MD

Department of Cardiology, University Hospital, Bern, Switzerland

Department of Cardiology, University Hospital Bern, Bern 3010, SwitzerlandSearch for more papers by this author
First published: 30 November 2011
Citations: 18

Conflict of interest: BM has received research grants and speaker fees from AGA-St. Jude Medical.

Abstract

Background: Iatrogenic free wall cardiac perforation is a rare but serious complication encountered during percutaneous cardiac procedures, which usually leads to tamponade and death. Septal occluder devices have been developed for sealing intracardiac shunts but may be also used in this emergency setting. Methods and Results: We report a small series of five consecutive cases of iatrogenic heart perforations that were treated with implantation of Amplatzer Septal Occluders (ASO). In the first case, iatrogenic left ventricle (LV) perforation occurred during LV biopsy and could be closed up with a 4 mm ASO. In the second case, a 4 mm ASO was used for sealing of a right atrial perforation allocated to Port-a-Cath dislodgment. The third case happened during transseptal puncture for implantation of a TandemHeart bVAD device in a patient suffering cardiogenic shock and was treated by implantation of a 5 mm ASO. The fourth patient was transferred to our facilities for percutaneous closure of an acute post-infarct VSD after anteroseptal myocardial infarction. This procedure was complicated by perforation of the posterolateral free wall and led to the deployment of 12 mm ASO. The last patient suffered from free LV wall perforation during investigation of a severe aortic stenosis and was treated by implantation of 4 mm ASO. All patients were alive after 24 hrs but the last patient died during the in-hospital stay of a right ventricular infarction complicated by multiple organ failure. Conclusions: Percutaneous device occlusion of iatrogenic heart perforation seems to be a safe and efficient method to treat iatrogenic heart perforation. In order to perform this elegant method, it is however imperative not to prematurely withdraw the perforating catheter to maintain access to the hole for closure. © 2011 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.